Carl Di Casoli

Statistics

Publications

Citations

108

H-Index

Active since

2020

Affiliations

Apellis Pharmaceuticals (United States)(Current)

Carl Di Casoli is an author at Apellis Pharmaceuticals (United States) specializing in clinical pharmacology, paroxysmal nocturnal hemoglobinuria therapy, and clinical hematology.

Publications per year

2020–2020

Publications

<scp>C3</scp> inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab

Carlos de Castro, F Grossi, Ilene C. Weitz et al. · American Journal of Hematology · 2020 · 98 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

C3 Inhibition with Pegcetacoplan Targets the Underlying Disease Process of C3 Glomerulopathy (C3G) and Improves Proteinuria

Bradley P. Dixon, Larry A. Greenbaum, Liwei Huang et al. · Journal of the American Society of Nephrology · 2020 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +17

1–2 of 2